Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term SURGICAL ADJUVANT BREAST. Found 12 abstracts

Gradishar WJ, Anderson BO, Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A, Giordano SH, Goldstein LJ, Hayes DF, Hudis CA, Isakoff SJ, Ljung BM, Marcom PK, Mayer IA, McCormick B, Miller RS, Pegram M, Pierce LJ, Reed EC, Salerno KE, Schwartzberg LS, Smith ML, Soliman H, Somlo G, Ward JH, Wolff AC, Zellars R, Shead DA, Kumar R, Nccn. Breast Cancer Version 3.2014 Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network. 2014 Apr;12(4):542-90.   PMCID: No NIH funds
Fang CY, Cherry C, Devarajan K, Li TY, Malick J, Daly MB. A prospective study of quality of life among women undergoing risk-reducing salpingo-oophorectomy versus gynecologic screening for ovarian cancer. Gynecologic Oncology. 2009 Mar;112(3):594-600.   PMCID: PMC2697574
Jordan VC. A Century of Deciphering the Control Mechanisms of Sex Steroid Action in Breast and Prostate Cancer: The Origins of Targeted Therapy and Chemoprevention. Cancer Research. 2009 Feb;69(4):1243-54.
Maximov PY, Lewis-Wambi JS, Jordan VC. The Paradox of Oestradiol-Induced Breast Cancer Cell Growth and Apoptosis. Current Signal Transduction Therapy. 2009 May;4(2):88-102.   PMCID: PMC2757321
Visvanathan K, Chlebowski RT, Hurley P, Col NF, Ropka M, Collyar D, Morrow M, Runowicz C, Pritchard KI, Hagerty K, Arun B, Garber J, Vogel VG, Wade JL, Brown P, Cuzick J, Kramer BS, Lippman SM. American Society of Clinical Oncology Clinical Practice Guideline Update on the Use of Pharmacologic Interventions Including Tamoxifen, Raloxifene, and Aromatase Inhibition for Breast Cancer Risk Reduction. Journal of Clinical Oncology. 2009 Jul;27(19):3235-58.   PMCID: PMC 2716943
Bane AL, Beck JC, Bleiweiss I, Buys SS, Catalano E, Daly MB, Giles G, Godwin AK, Hibshoosh H, Hopper JL, John EM, Layfield L, Longacre T, Miron A, Senie R, Southey MC, West DW, Whittemore AS, Wu H, Andrulis IL, O'Malley FP. BRCA2 mutation-associated breast cancers exhibit a distinguishing phenotype based on morphology and molecular profiles from tissue microarrays. American Journal of Surgical Pathology. 2007 Jan;31(1):121-8.
Chang DT, Feigenberg SJ, Indelicato DJ, Morris CG, Lightsey J, Grobmyer SR, Copeland EM, Mendenhall NP. Long-term outcomes in breast cancer patients with ten or more positive axillary nodes treated with combined-modality therapy: The importance of radiation field selection. International Journal of Radiation Oncology Biology Physics. 2007 Mar;67(4):1043-51.
Jordan VC. Opinion - Chemoprevention of breast cancer with selective oestrogen-receptor modulators. Nature Reviews Cancer. 2007 Jan;7(1):46-53.
Jordan VC. Successful translation research with selective oestrogen receptor modulators to treat and prevent breast cancer. Geburtshilfe Und Frauenheilkunde. 2007 May;67(5):443-50.
Jordan VC, Brodie AM. Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer. Steroids. 2007 Jan;72(1):7-25.
Jordan VC, O'Malley BW. Selective estrogen-receptor modulators and antihormonal resistance in breast cancer. Journal of Clinical Oncology. 2007 Dec;25(36):5815-24.
Osipo C, Meeke K, Cheng D, Weichel A, Bertucci A, Liu H, Jordan VC. Role for HER2/neu and HER3 in fulvestrant-resistant breast cancer. International Journal of Oncology. 2007 Feb;30(2):509-20.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term SURGICAL ADJUVANT BREAST

SURGICAL ADJUVANT BREAST BOWEL PROJECT P-1 POSTMENOPAUSAL WOMEN RANDOMIZED-TRIAL breast cancer MAMMARY-CARCINOMA MODEL tamoxifen ATHYMIC MICE TAMOXIFEN RESISTANCE RANDOMIZED AROMATASE INHIBITOR LETROZOLE ESTROGEN-RECEPTOR PROGESTERONE-RECEPTOR estrogen receptor BRCA2 QUALITY-OF-LIFE THERAPY LONG-TERM TAMOXIFEN GROWTH-FACTOR RECEPTOR 474 ICI 46 SUPPRESS AROMATASE EXPRESSION SENTINEL-NODE BIOPSY antihormone resistance PSYCHOLOGICAL IMPACT POSTMASTECTOMY RADIOTHERAPY selective oestrogen receptor modulators MENOPAUSE SYNTHESIS INVITRO RISK ANTIESTROGENS Screening ITALIAN RANDOMIZED-TRIAL familial NEGATIVE MAMMARY-TUMORS EMISSION TOMOGRAPHY HIGH-DOSE CHEMOTHERAPY OVARIAN-CANCER ENDOMETRIAL CANCER raloxifene PLACEBO-CONTROLLED TRIAL WOMEN genetics neu PREVENTION TRIAL prevention ANTIAPOPTOTIC TUMOR CHARACTERISTICS aromatase inhibitors CONTINUING OUTCOMES RELEVANT CONSERVING THERAPY PREVENTION 4-hydroxyandrostenedione PHASE-II TRIAL adverse effects CLINICAL-TRIAL SERM Breast cancer BONE-MINERAL DENSITY Quality of life GERMLINE MUTATIONS ER-ALPHA apoptosis CONSERVATIVE SURGERY lymph nodes TUMOR-GROWTH TRIAL AROMATASE INHIBITOR LOW-DOSE TAMOXIFEN fulvestrant oestrogen receptor ABDOMINAL HYSTERECTOMY SYMPTOMS CARRIERS ANDROGEN RECEPTOR MODULATORS GENE-TRANSCRIPTION BCL-2-FAMILY PROTEINS IN-SITU HYBRIDIZATION COMPUTED TOMOGRAPHY PROLACTIN radiotherapy biomarkers breast neoplasms combined-modality therapy oestrogen action HER2 CELLS-IN-VITRO electrons REGIONAL NODAL PREMENOPAUSAL WOMEN RALOXIFENE CYCLOPHOSPHAMIDE FAMILY REGISTRY Oncology CYP2D6 GENOTYPE LYMPH-NODES AUTOLOGOUS BONE-MARROW ANTI-TUMOUR AGENT ACTIVATED PROTEIN-KINASE SURVIVAL DOUBLE-BLIND CANCER MUTATIONS Ovarian cancer DOXORUBICIN PLUS SKIN-SPARING MASTECTOMY TISSUE-CULTURE adjuvant CONTROLLED-TRIAL HIGH-RISK FIRST-LINE PREMATURE SMALL-MOLECULE INHIBITOR Prophylactic surgery PROPHYLACTIC OOPHORECTOMY EPIDERMAL GROWTH-FACTOR ESTROGEN-RECEPTOR STATUS IRRADIATION ESTROGEN-RECEPTOR-ALPHA IMMUNOHISTOCHEMICAL MARKERS DICS 474 TAMOXIFEN ICI 46 TYROSINE KINASE INHIBITOR pathology ENDOMETRIAL EARLY-STAGE
Last updated on Saturday, June 06, 2020